1,3-萘啶-2(1h)-酮 | 54920-82-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,3-萘啶-2(1h)-酮
• 中文别名: 2-羟基-1,7-萘啶；1,3-萘啶-2(H)-酮
• 英文名称: 1H-1,7-naphthyridin-2-one
• 英文别名: 2-Hydroxy-1,7-naphthyridin
• CAS: 54920-82-0
• 化学式: C₈H₆N₂O
• mdl: MFCD11521584
• 分子量: 146.15
• InChiKey: FQAJSEWFBJSSOY-UHFFFAOYSA-N

物化性质

• 熔点：
  290-291 °C(Solv: water (7732-18-5))
• 沸点：
  391.8±42.0 °C(Predicted)
• 密度：
  1.267±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  1,3-萘啶-2(1h)-酮 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 19.0h， 生成 2-(2-fluoro-4-pyridyl)-1,7-naphthyridine
  参考文献：
  名称：

  Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase

  摘要：

  The TRAF2 and NCK interacting kinase (TNIK) has been proposed to play a role in cytoskeletal organization and synaptic plasticity and has been linked, among others, to neurological disorders. However, target validation efforts for TNIK have been hampered by the limited kinase selectivity of small molecule probes and possible functional compensation in mouse models. Both issues are at least in part due to its close homology to the kinases MINK1 (or MAP4K6) and MAP4K4 (or HGK). As part of our interest in validating TNIK as a therapeutic target for neurological diseases, we set up a panel of biochemical and cellular assays, which are described herein. We then examined the activity of known amino-pyridine-based TNIK inhibitors (1, 3) and prepared structurally very close analogs that lack the ability to inhibit the target. We also developed a structurally orthogonal, naphthyridine-based TNIK inhibitor (9) and an inactive control molecule of the same chemical series. These validated small-molecule probes will enable dissection of the function of TNIK family in the context of human disease biology.

  DOI：

  10.1016/j.bmcl.2019.05.032

文献信息

• [EN] PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE ET LEUR UTILISATION COMME INHIBITEURS DU RÉCEPTEUR P2X7
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2009057827A1

  公开（公告）日：2009-05-07

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  翻译结果为：新型的哒嗪酮化合物，其化学公式为(I)，能够抑制嘌呤能P2X7受体，并对预防、治疗和改善炎症性和免疫性疾病有益。
• [EN] NRF2 ACTIVATOR<br/>[FR] ACTIVATEUR DE NRF2
  申请人：BIOGEN MA INC

  公开号：WO2018140876A1

  公开（公告）日：2018-08-02

  Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.

  提供了四氢异喹啉衍生物作为Nrf2激活剂。
• [EN] 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS<br/>[FR] ANALOGUES DE 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE
  申请人：ZENO ROYALTIES & MILESTONES LLC

  公开号：WO2019028008A1

  公开（公告）日：2019-02-07

  Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

  本文提供了式（I）的化合物。这些化合物以及其药学上可接受的盐和组合物对于治疗疾病或症状是有用的，包括那些以细胞过度增殖为特征的病症，比如乳腺癌。
• [EN] 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER<br/>[FR] [1,8]-NAPHTYRIDINES SUBSTITUÉES PAR 2,4-DIARYLE EN TANT QU'INHIBITEURS DE KINASE, DESTINÉES À UNE UTILISATION CONTRE LE CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2012000595A1

  公开（公告）日：2012-01-05

  The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

  本发明涉及新型[1,8]萘啶衍生物的化学式(I)，以及利用这类化合物在ATP消耗蛋白质如激酶中抑制、调节和/或调制信号传导的用途，特别是TGF-beta受体激酶的抑制剂，以及利用这类化合物治疗激酶诱导的疾病，尤其是肿瘤的治疗。
• [EN] NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES TÉTRAHYDROISOQUINOLINES ET TÉTRAHYDRONAPHTHYRIDINES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018083136A1

  公开（公告）日：2018-05-11

  The present invention provides novel compounds having the general formula (I): wherein R1, R 2, R 3, U, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供了具有通式（I）的新化合物，其中R1、R2、R3、U、V、W、X和Y如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。